	US 12,246,016 B2
	Therapeutic use of afatinib in cancer
Jordi Surrallés Calonge, Barcelona (ES); Jordi Minguillón Pedreño, Barcelona (ES); and Helena Montanuy Escribano, Barcelona (ES)
Assigned to UNIVERSITAT AUTÒNOMA DE BARCELONA, Bellaterra (ES); CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED, M.P, Bellaterra (ES); and FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU, Barcelona (ES)
Appl. No. 17/260,990
Filed by UNIVERSITAT AUTÒNOMA DE BARCELONA, Barcelona (ES); CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED, M.P., Madrid (ES); and FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU, Barcelona (ES)
PCT Filed Jul. 15, 2019, PCT No. PCT/EP2019/069039 § 371(c)(1), (2) Date Jan. 15, 2021, PCT Pub. No. WO2020/016191, PCT Pub. Date Jan. 23, 2020.
Claims priority of application No. 18382527 (EP), filed on Jul. 16, 2018.
Prior Publication US 2021/0290622 A1, Sep. 23, 2021
Int. Cl. A61K 31/517 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/517 (2013.01) [A61P 35/00 (2018.01)]

15 Claims

1. A method for the treatment of cancer, wherein the cancer is selected from leukemia, a squamous cell carcinoma, and hepatocellular carcinoma, in a patient suffering from a disease caused by a defect in DNA damage repair mechanism, wherein the disease is Fanconi anemia, the method comprising administering a therapeutically effective amount of afatinib or a pharmaceutical salt thereof to the patient in need thereof.